With the increasing emergence of antibiotic resistances old antibiotics became a valuable 21 source to find agents suitable to address this problem. More than 20 years after the last report, 22 our purpose was to re-evaluate the in vitro antibacterial activity of the topical agent primycin 23 against current important bacterial pathogens. Minimal inhibitory concentrations (MIC) and 24 minimal bactericidal concentrations (MBC) of primycin were tested in comparison with 25 agents widely applied topically, and with those of mupirocin and vancomycin, the topical and 26 the non-topical gold-standard anti-MRSA agents. Primycin was ineffective (MIC>64 μg/ml) 27 against all the Gram-negative isolates tested. On the other hand, all the tested Gram-positive 28 isolates were susceptible with MIC 90 values of 0.06 μg/ml for staphylococci and 0.5-1 μg/ml 29 for enterococci, streptococci, and P. acnes isolates, including all the multiresistant strains. 30
MIC testing 148
The MIC of each isolate was determined by broth microdilution method according to the 149 CLSI standards (2012 a, 2012 b). For susceptibility testing of aerobically growing bacteria, 150
Mueller Hinton broth (Biolab, Hungary) was used. Cation-adjusted Mueller-Hinton broth 151 (Biolab, Hungary) supplemented with 5% (v/v) lysed horse blood (Liofilchem, Italy) was 152 used for Streptococcus spp. including S. pneumoniae isolates. When testing daptomycin, Ca 2+ 153 content of the broth was adjusted to 50 μg/ml. In case of P. acnes isolates Brucella Broth 154 (Biolab, Hungary) supplemented with 1 μg/ml vitamin K1, 5 μg/ml hemin, and 5% (v/v) lysed 155 horse blood was applied. Concentration ranges for the individual agents were as follows: 156 primycin and oxacillin: 0.015-64 μg/ml; vancomycin, oxytetracycline, tobramycin, andneomycin: 0.06-32 μg/ml; gentamicin, erythromycin, ofloxacin, and daptomycin: 0.03-16 158 μg/ml; mupirocin: 0.03-1024 μg/ml. The inocula of test strains were prepared in sterile 0.9 % 159 w/v saline solution from overnight plate cultures, and adjusted to 0.5 McFarland unit, and. 160 diluted into the broth medium to reach the working concentration of approximately 5 × 10 5 161 colony forming units (CFU) per ml. Isolates of aerobically growing species were incubated 162 for 20-24 hours at 37 °C in ambient air while P. acnes isolates were incubated for 48 hours at 163 37 °C under anaerobic condition, prior to MIC reading. The MIC was defined as the lowest 164 antibiotic concentration at which no growth was detectable with the unaided eye compared to 165 the control wells. CLSI quality control MIC ranges were applied for ofloxacin, tobramycin, 166 erythromycin, gentamicin, mupirocin, vancomycin, oxacillin, and daptomycin (CLSI, 2014) . 167
For neomycin we considered target MICs to be 1 and 4 μg/ml for S. aureus ATCC 29213 and 168 E. coli ATCC 25922, respectively, reported by Bera et al. (2010) . In case of oxytetracycline 169 target MIC of 1 μg/ml for E. coli ATCC 25922 was applied according to Miller et al. (2005) . 170
At least two independent experiments were performed in duplicates for every isolate. 171
172

MBC testing 173
Minimal bactericidal concentration (MBC) testing was performed in accordance with the 174 CLSI guideline (1999). Duplicate samples of 0.01 ml taken from wells showing no growth 175 were subcultured on agar plates (blood agar for streptococci and anaerobic blood agar for P. 176 acnes isolates) immediately after the MIC reading. Colonies were counted after 20-24 h 177 incubation at 37 °C in ambient air (anaerobic incubation at 37 °C for 48 h for P. acnes 178 isolates). The MBC was defined as the lowest concentration causing ≥3 log 10 decrease of CFU 179 count resulting in no more than five colonies on the plates. 180 181
Time-kill assays 182
Time-kill assays were also performed according to the CLSI guideline (1999). Test media and 183 preparation of inoculum suspensions were the same as for the MIC measurements. 184
Antimicrobial concentrations of one-, two-, four-, and eight-fold of the MICs were applied. 185
The initial inoculum concentration was aimed to be 5 × 10 5 CFU/ml. Reaction tubes with 10 186 ml final volume were incubated at 37 °C in ambient air for 24 hours. Serial tenfold dilutions 187 of 0.1 ml samples removed at 0, 1, 2, 4, 8, 12, and 24 h were made in sterile 0.9 % w/v saline 188 solution, and 0.01 ml aliquots of these suspensions and the undiluted sample were cultured in 189 duplicates on agar plates similar to those used in MBC measurements. Colonies were counted 190 after incubation similar to that of MBC plate cultures. Limit of detection was 1.7 log 10 191 CFU/ml. Effects resulting ≥3 log 10 decrease in CFU counts were interpreted as bactericidal. 
Susceptibility test results 213
In the susceptibility tests all of the examined Gram-positive clinical isolates proved to be 214 susceptible to primycin, showing unimodal MIC distribution within genera ( The only exception was the ATCC 700699 VISA strain, being the only S. aureus to reach a 237 primycin MIC value of 0.125 μg/ml -double of all the others' (Table 5) . 238
As the mupirocin-resistant S. aureus ATCC BAA-1708 also proved to be sensitive to 239 primycin, we made a comparison of primycin with mupirocin on an extended collection of 240 MRSA -the target organism of mupirocin in its primary indication of nasal decolonization (Table 6 ). Only one out of 20 MRSA clinical isolates showed high level mupirocin resistance, 242 the rest of the isolates were sensitive with low MIC values. Primycin generally showed MIC 243 and MBC values one or two dilutions lower than mupirocin, and the mupirocin-resistant 244 MRSA clinical isolate also proved to be susceptible to primycin. 245 246
Time-kill curves 247
To assess the dynamics of the bactericidal effect of primycin, time-kill studies were 248 performed on three reference strains, S. aureus ATCC 29213, E. faecalis ATCC 29212, and S. respectively. The agent showed bacteriostatic effect against E. faecalis ATCC 29212 (Fig. 2) . 263
The time-kill results harmonized well with the corresponding MIC and MBC values. 264
265
Frequency of spontaneous resistance to primycin 266
To assess frequency of spontaneous primycin-resistant mutants, eight reference strains were 267 involved in single-step spontaneous mutation studies: S. aureus ATCC 29213, S. aureus 268 aureus BAA-1708, E. faecalis ATCC 29212, and E. faecalis 51299. 270
No resistant colony was found in these experiments (mutant frequency <4.5 × 10 -9 for all the 271 strains tested). For the S. aureus ATCC 25923 strain, previously reported to be resistant to 272 primycin (Úri and Actor, 1979) , the experiment was also performed by challenging a two 273 exponent larger population, but again, no resistant mutant emerged (mutant frequency <2.7 × 274 10 -11 ). 275 276
Results of the passaging experiments 277
While spontaneous resistant mutants did not emerge during the single-step mutation tests, we 278 conducted a 21-day passaging study with the same strains in order to assess the selection of 279 resistant mutants which we could also use to assess possible phenotypic cross-resistance with 280 other antimicrobials. 281
Only one isolate could reach fourth, and six others twice the initial MIC value, while one 282 isolate failed to change its MIC value during the 21-day period (Table 7) Resistance to antimicrobials is a high priority health care issue attracting worldwide attention. 312
The emergence and spread of multiresistant bacteria stimulated numerous studies to develop 313 more effective antibacterial agents, and also induced re-evaluation of previously known 314 compounds not being in the focus of the present therapeutic palette. Our study effectuates the 315 latter approach on primycin by re-investigating the efficacy of this topical agent introduced 316 more than 50 years ago but not widely used in the present practice. 
